Your browser is no longer supported. Please, upgrade your browser.
Settings
BIIB Biogen Inc. daily Stock Chart
BIIB [NASD]
Biogen Inc.
IndexS&P 500 P/E10.58 EPS (ttm)21.72 Insider Own0.10% Shs Outstand197.40M Perf Week1.19%
Market Cap45.38B Forward P/E7.69 EPS next Y29.89 Insider Trans40.28% Shs Float195.78M Perf Month-1.30%
Income4.45B PEG2.67 EPS next Q6.85 Inst Own93.50% Short Float1.82% Perf Quarter-30.94%
Sales13.45B P/S3.37 EPS this Y24.50% Inst Trans0.08% Short Ratio1.51 Perf Half Y-27.14%
Book/sh65.26 P/B3.52 EPS next Y3.48% ROA17.60% Target Price261.19 Perf Year-12.31%
Cash/sh17.92 P/C12.83 EPS next 5Y3.96% ROE33.40% 52W Range216.12 - 388.67 Perf YTD-23.60%
Dividend- P/FCF7.47 EPS past 5Y22.70% ROI23.60% 52W High-40.85% Beta1.02
Dividend %- Quick Ratio2.00 Sales past 5Y14.20% Gross Margin86.50% 52W Low6.37% ATR9.08
Employees7800 Current Ratio2.30 Sales Q/Q6.60% Oper. Margin43.80% RSI (14)36.38 Volatility3.30% 2.82%
OptionableYes Debt/Eq0.46 EPS Q/Q17.00% Profit Margin32.90% Rel Volume1.07 Prev Close224.40
ShortableYes LT Debt/Eq0.46 EarningsApr 24 BMO Payout0.00% Avg Volume2.36M Price229.89
Recom2.80 SMA20-1.27% SMA50-17.75% SMA200-27.84% Volume2,508,516 Change2.45%
Apr-10-19Resumed Raymond James Mkt Perform
Mar-25-19Reiterated H.C. Wainwright Buy $363 → $300
Mar-22-19Reiterated BMO Capital Markets Market Perform $322 → $250
Mar-22-19Downgrade UBS Buy → Neutral $395 → $242
Mar-22-19Downgrade Morgan Stanley Overweight → Underweight $401 → $210
Mar-22-19Downgrade Canaccord Genuity Buy → Hold $396 → $275
Mar-21-19Reiterated Guggenheim Neutral $325
Mar-21-19Downgrade William Blair Outperform → Mkt Perform
Mar-21-19Downgrade Wells Fargo Outperform → Market Perform
Mar-21-19Downgrade Mizuho Buy → Neutral
Mar-21-19Downgrade JP Morgan Overweight → Neutral
Mar-21-19Downgrade Goldman Buy → Neutral
Mar-21-19Downgrade Citigroup Buy → Neutral
Mar-21-19Downgrade BofA/Merrill Buy → Neutral
Mar-21-19Downgrade Atlantic Equities Overweight → Neutral
Feb-21-19Downgrade Stifel Buy → Hold $397 → $346
Dec-21-18Initiated BTIG Research Buy
Oct-19-18Downgrade Bernstein Outperform → Mkt Perform
Oct-08-18Reiterated Citigroup Buy $483 → $470
Oct-01-18Resumed Cantor Fitzgerald Overweight $400
Apr-25-19 04:37PM  Jerome Dodson's 1st Quarter Parnassus Endeavor Fund Commentary GuruFocus.com
03:47PM  Biogen Looks to 23 Clinical Programs for Growth Motley Fool
03:10PM  Bitcoin and Biogen among the second round 2019 Stock Draft picks CNBC Videos
02:46PM  Here is who's competing in the 2019 Stock Draft, the rules and the first pick CNBC Videos
12:18PM  IPO Cortexyme Hopes to Succeed in Alzheimer's Where Giants like Biogen Have Failed GuruFocus.com
10:36AM  Edited Transcript of BIIB earnings conference call or presentation 24-Apr-19 12:00pm GMT Thomson Reuters StreetEvents
10:04AM  AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters
10:01AM  AbbVie says Humira rivals from Biogen, Amgen most aggressive so far Reuters
08:27AM  Biogen says it will not give up on Alzheimers after failed trials MarketWatch
Apr-24-19 04:18PM  Biogen Won't Disavow Its Alzheimer's Goal So What's Next For Growth? Investor's Business Daily
03:44PM  Biogen Inc (BIIB) Q1 2019 Earnings Call Transcript Motley Fool
12:28PM  Biogen Earnings: BIIB Stock Slips Despite Q1 Beat InvestorPlace
12:25PM  Stocks making the biggest moves midday: AT&T, Domino's Pizza, eBay & more CNBC
11:40AM  Biogen (BIIB) Beats on Q1 Earnings, Spinraza Drives Sales Zacks
11:38AM  Biogen dips as strategy post Alzheimer's setback fails to impress Reuters
11:22AM  Biogen Stays the Wrong Course After a Key Drug Failure Bloomberg
10:24AM  You can find plenty of solid stock bargains in this years worst-performing sector, analysts say MarketWatch
10:04AM  Biogen Stock Slips Because Strong Earnings Cant Make Up for Its Failed Alzheimer Drug Barrons.com
10:04AM  Biogen Shares Fall After Drugmaker Meets Earnings Estimates TheStreet.com
08:36AM  Biogen (BIIB) Q1 Earnings & Sales Beat Estimates Zacks
07:33AM  Biogen stock up 1.8% in premarket trade after revenue beat MarketWatch
07:15AM  Biogen beats first-quarter profit estimates on Spinraza strength Reuters
06:51AM  Biogen first-quarter profit rises 20 percent on Spinraza strength Reuters
06:36AM  Biogen first-quarter profit rises 20 percent Reuters
02:33AM  Biogen Earnings, Revenue Beat in Q1 Investing.com
Apr-23-19 10:53PM  Biogen promises to plug pipeline gap after Alzheimers failure Financial Times
10:11AM  Health-care earnings: Medicare for all looms large MarketWatch
09:27AM  What's in Store for Celgene Corporation (CELG) Q1 Earnings? Zacks
08:15AM  Biogen Reports Earnings Tomorrow. Heres What to Expect. Barrons.com
Apr-22-19 05:00PM  Better Buy: Biogen vs. AbbVie Motley Fool
10:17AM  Biogen (BIIB) to Report Q1 Earnings: What's in the Cards? Zacks
08:30AM  Will Bristol-Myers (BMY) Disappoint This Earnings Season? Zacks
07:00AM  Patients living with Spinal Muscular Atrophy (SMA) in the province of Saskatchewan gain access to SPINRAZA (nusinersen) CNW Group
Apr-18-19 10:29AM  Roche's (RHHBY) Q1 Sales Strong on Solid Demand for New Drugs Zacks
Apr-17-19 02:34PM  Here's Why Ionis Pharmaceuticals Slumped Today Motley Fool
01:45PM  2 Beaten Down Bluechips: Are They Buys? Motley Fool
10:31AM  Biogen (BIIB) Reports Next Week: Wall Street Expects Earnings Growth Zacks
Apr-15-19 05:45PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
03:00PM  Seeking $86 million IPO, this Peninsula company is betting common bacteria plays role in Alzheimer's American City Business Journals
06:58AM  Goldman Sachs's 20 best stocks to invest in now Yahoo Finance
Apr-14-19 09:16AM  Better Buy: Gilead Sciences vs. Biogen Motley Fool
Apr-12-19 07:30AM  Biogen Continues to Advance Innovation in SMA with New Data in Adults and Infants to Be Presented at MDA Clinical and Scientific Conference GlobeNewswire
Apr-11-19 06:33AM  Risk-Tolerant Investors, Turn Your Eyes to Exelixis Stock InvestorPlace
12:00AM  An AI Firm Wants to Predict Costly Pharma Flops Bloomberg
Apr-10-19 09:59AM  Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds Benzinga
Apr-09-19 05:45PM  Biogen (BIIB) Dips More Than Broader Markets: What You Should Know Zacks
05:01PM  6 Predictable Guru Stocks GuruFocus.com
Apr-07-19 11:59PM  Sarissa Capital Management Hires New President Insider Monkey
Apr-06-19 06:13PM  Should Biogen Investors Be Extra Nervous Right Now? Motley Fool
Apr-04-19 03:54PM  Here's What Biogen Inc.'s (NASDAQ:BIIB) P/E Ratio Is Telling Us Simply Wall St.
02:49PM  1 Biotech That Biogen Should Buy ... but Probably Won't Motley Fool
01:28PM  Buy Biogen on the dip? What about AMC on the streaming wars? The viewers #AskHalftime CNBC Videos
09:57AM  Why Biogen Stock Tanked in March Motley Fool
09:03AM  MOVES-Activist hedge fund Sarissa hires president in push for growth Reuters
Apr-03-19 06:08PM  Biogen SMA drug price, Novartis estimates for its treatment far too high: U.S. group Reuters
05:41PM  Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group Reuters
04:37PM  Biogen SMA drug price, Novartis estimates for its treatment far too high -U.S. group Reuters
08:21AM  Why Nightstar Therapeutics Stock Skyrocketed 71% in March Motley Fool
Apr-02-19 11:58AM  3 Healthcare Stocks to Trade Now InvestorPlace
10:10AM  Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report? Zacks
Apr-01-19 04:24PM  Celgene Gets Positive CHMP Nod for Revlimid Label Expansion Zacks
02:56PM  These are the 20 most valuable brands in Massachusetts American City Business Journals
01:46PM  3 High Earnings-Yield Stocks GuruFocus.com
10:41AM  Merck KgaA's (MKGAF) MS Drug Mavenclad Gets FDA Approval Zacks
Mar-30-19 12:00PM  3 Leading Alzheimer's Disease Drugs in Development After Biogen's Aducanumab Flop Motley Fool
05:46AM  Are the health care stocks flat lining? Here are the beaten down names traders are still buying CNBC Videos
Mar-29-19 10:36AM  4 Small Biotech Stocks Likely to Witness More Upside in 2019 Zacks
Mar-28-19 04:34PM  Is Biogen a Beat-Up Bargain? And Is Bristol-Myers' Mega-Merger on the Rocks? Motley Fool
12:04PM  Why Biogen's Alzheimer's Drug Failure May Have a Silver Lining Motley Fool
Mar-27-19 07:19PM  The 5 Worst-Performing Stocks in the S&P 500 in 2019 GuruFocus.com
07:07PM  3 High-Quality, Low Price-Earnings Companies Broadly Owned by Gurus GuruFocus.com
06:50PM  Is Biogen Inc. (BIIB) A Good Stock To Buy? Insider Monkey
06:13PM  Novartis (NVS) Receives FDA Approval for MS Drug Mayzent Zacks
04:12PM  The Hits Just Keep Coming For Biogen As Rival Gains MS Drug Approval Investor's Business Daily
10:55AM  Biotech Stock Roundup: BIIB & CNAT Crash on Study Failures, LXRX Gets CRL Zacks
10:00AM  Future Brightens for 2 Small Biotech Stocks TheStreet.com
07:00AM  Biogen Remains a Wide-Moat Neurology Innovator Morningstar
06:00AM  Biogen- A Bad News Biotech Buy MoneyShow
Mar-26-19 05:15PM  Celgene (CELG) Submits NDA for MS Drug to FDA for Review Zacks +5.74%
04:28PM  Why Viacom, Ferroglobe, and Biogen Jumped Today Motley Fool
12:51PM  Stocks - Dow Ends Higher, but Gains Capped by Weak Economic Data Investing.com
11:18AM  AbbVie's Psoriasis Drug Skyrizi Gets First Approval in Japan Zacks
10:24AM  Biogen's Bad News for Everyone Motley Fool
07:25AM  Detailed Research: Economic Perspectives on Biogen, Invesco, Bunge, Concho Resources, Maximus, and Meredith What Drives Growth in Today's Competitive Landscape GlobeNewswire
Mar-25-19 04:24PM  Dow Ends Slightly Higher Despite Slowing Global Growth Worries TheStreet.com
03:15PM  3 Top Healthcare Stocks to Buy Right Now Motley Fool
02:48PM  1 Surprising Reason Alzheimer's Drugs Remain So Elusive Motley Fool
12:04PM  Dow Jones Recovers After 130-Point Drop; Marijuana Stocks Rally, Led By Cronos Group Investor's Business Daily
10:39AM  Biogen Stock Likely Wont See a Boost From Buybacks, Analysts Say Barrons.com
09:56AM  Biogen announces $5 billion buyback days after shelving Alzheimer's trials Reuters
09:41AM  Biogen Announces $5 Billion Buyback Just Days After Stock Plunge TheStreet.com
09:01AM  Avon and Biogen Gain, and 3 Other Stocks Making Moves Barrons.com
08:49AM  5 biotech stocks that could be the next big winners MarketWatch
08:32AM  Biogen announces $5 billion buyback days after shelving Alzheimer's trials Reuters
07:26AM  Biogen sets new $5 billion stock repurchase program in aftermath of stock plunge MarketWatch
06:55AM  Biogen stock plummets 28% after company halts Alzheimers trials MarketWatch
04:05AM  Stocks - Viacom Jumps in Premarket, Nike, Apple Drop, Boeing Gains Investing.com
Mar-24-19 01:00PM  Is It Safe to Buy Biogen Stock Right Now? InvestorPlace
Mar-23-19 12:20PM  The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs Benzinga
10:02AM  2 Biotech Takeout Targets Perfect for Biogen Motley Fool
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases worldwide. The company offers TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for the treatment of multiple sclerosis (MS); SPINRAZA for the treatment of spinal muscular atrophy; and FUMADERM for the treatment of plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; FLIXABI, an infliximab biosimilar referencing REMICADE; and IMRALDI, an adalimumab biosimilar referencing HUMIRA. In addition, the company offers RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for the treatment of primary progressive MS and relapsing MS, and other anti-CD20 therapies. Further, it is involved in developing BIIB098, Opicinumab, and BIIB061 for MS and neuroimmunology; Aducanumab, Elenbecestat, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB092 and BIIB054 for treating Parkinson's disease and movement disorders; BIIB067, BIIB078, and BIIB110 to treat neuromuscular disorders; BIIB093, TMS-007, and Natalizumab to treat acute neurology; BIIB104 for treating neurocognitive disorders; BIIB074 and BIIB095 for pain; and Dapirolzumab pegol, BG00011, and BIIB059 for treating other diseases, which are under various stages of development. The company offers products through its sales force and marketing groups. Biogen Inc. has collaboration agreements with Genentech, Inc., Eisai Co., Ltd., Alkermes Pharma Ireland Limited, Bristol-Myers Squibb Company, Acorda Therapeutics, Inc., AbbVie Inc., C4 Therapeutics, University of Pennsylvania, Applied Genetic Technologies Corporation, and others. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PANGIA ROBERT WDirectorMar 18Option Exercise52.226,114319,27324,701Mar 19 04:08 PM
PANGIA ROBERT WDirectorMar 18Sale328.556,1142,008,75518,587Mar 19 04:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechMar 01Option Exercise0.0056807,488Mar 05 04:17 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 22Option Exercise38.518,058310,28536,085Feb 26 05:09 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 22Option Exercise0.001,663011,148Feb 26 05:07 PM
Vounatsos MichelChief Executive OfficerFeb 15Option Exercise0.005,269018,914Feb 20 06:10 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 15Option Exercise0.001,318010,071Feb 20 06:08 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 15Option Exercise0.001,44807,968Feb 20 06:07 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 15Option Exercise0.001,68508,526Feb 20 05:54 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 15Option Exercise0.001,685028,776Feb 20 05:53 PM
Vounatsos MichelChief Executive OfficerFeb 12Option Exercise0.006,899016,267Feb 14 06:33 PM
Sandrock AlfredEVP, Chief Medical OfficerFeb 12Option Exercise0.004,64309,452Feb 14 06:29 PM
McKenzie PaulEVP Pharmaceutical Oper & TechFeb 12Option Exercise0.003,06207,059Feb 14 06:17 PM
Gregory GingerEVP, Human ResourcesFeb 12Option Exercise0.001,83602,561Feb 14 06:10 PM
Ehlers Michael DEVP, Research and DevelopmentFeb 12Option Exercise0.003,82707,639Feb 14 06:07 PM
ALEXANDER SUSAN HEVP Chief Legal Officer & Sec.Feb 12Option Exercise0.003,268027,710Feb 14 06:04 PM
DENNER ALEXANDER JDirectorFeb 01Buy328.457,0002,299,163524,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 31Buy330.5225,8008,527,393517,658Feb 01 04:19 PM
DENNER ALEXANDER JDirectorJan 30Buy324.8630,0009,745,851491,858Feb 01 04:19 PM
CAPELLO JEFFREY DEVP & Chief Financial OfficerJan 02Option Exercise0.001,33101,331Jan 04 04:17 PM
Guindo ChirfiEVP Glob. Mkt Acc & Cust InnovDec 01Option Exercise0.0060202,721Dec 04 08:21 PM
Ehlers Michael DEVP, Research and DevelopmentSep 26Sale350.001,000350,0004,281Sep 27 04:16 PM
Gregory GingerEVP, Human ResourcesAug 01Option Exercise0.0026201,122Aug 03 04:14 PM
Ehlers Michael DEVP, Research and DevelopmentJun 01Option Exercise0.001,38405,897Jun 05 04:31 PM
Vounatsos MichelChief Executive OfficerMay 02Option Exercise0.001,687010,118May 04 06:09 PM